CAMKK2 PROTACs for Tumor Growth Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer and obesity lack effective therapeutic strategies that target CAMKK2, a key enzyme involved in tumor growth and metabolic regulation.
Innovation Solution
Development of compounds that specifically target CAMKK2 for degradation, using proteolysis targeting chimeras (PROTACs) to harness the ubiquitin-proteasome pathway for therapeutic purposes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments are used, then tumor growth is inhibited to some extent, but they fail to specifically target CAMKK2 and cannot effectively reprogram the tumor microenvironment
Solution Approach 1:
The patent extracts and isolates CAMKK2 as the specific therapeutic target from the complex tumor microenvironment. By using PROTACs that specifically bind to CAMKK2, the invention selectively removes this key enzyme responsible for tumor growth and immune suppression, thereby achieving both high specificity and effective tumor growth suppression.
Solution Approach 2:
The patent introduces PROTACs as intermediary molecules that mediate between the therapeutic agent and CAMKK2. These bivalent molecules consist of an E3 ligase ligand connected through a linker to a small molecule that binds to CAMKK2, enabling precise targeting and degradation of the enzyme while maintaining high specificity and effectiveness.
2Productivity
If CAMKK2 inhibition is achieved through conventional inhibitors, then tumor growth is suppressed, but the inhibitors lack the ability to induce protein degradation and reprogram the microenvironment
Solution Approach 1:
The patent extracts the limitation of conventional inhibitors that only block enzyme activity without inducing degradation. By using PROTACs that target CAMKK2 for proteasome-mediated degradation, the invention completely removes the enzyme from the system, thereby achieving both tumor growth suppression and microenvironment reprogramming simultaneously.
Solution Approach 2:
The patent changes the mechanism of action from enzyme inhibition to protein degradation. This parameter change enables the therapeutic to not only block CAMKK2 function but also eliminate the enzyme entirely, leading to sustained tumor growth suppression and durable microenvironment reprogramming.
3Reliability
If PROTACs are used to target CAMKK2, then specific degradation is achieved, but the complexity of the PROTAC molecule increases
Solution Approach 1:
The patent segments the PROTAC molecule into distinct functional components: an E3 ligase ligand portion, a linker moiety, and a small molecule CAMKK2 binder. This segmentation allows each component to be optimized independently for its specific function while maintaining overall molecular feasibility and reducing excessive complexity.
Solution Approach 2:
The patent designs the PROTAC framework to be multi-functional, where a single molecule simultaneously binds to CAMKK2, recruits the proteasome, and mediates degradation. This multi-functionality reduces the need for multiple separate agents, thereby simplifying the overall therapeutic approach despite the inherent complexity of PROTACs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively degrade CAMKK2, leading to suppressed tumor growth, enhanced immune response within the tumor microenvironment, and potential weight loss benefits, thus offering a novel therapeutic approach for cancer and obesity.
Implementation Method 1
Protein degradation is a highly regulated and essential process that maintains cellular homeostasis. Selective identification and removal of damaged, misfolded, or excess proteins is achieved through the ubiquitin-proteasome pathway (UPP).
Implementation Method 2
One promising therapy uses proteolysis targeting chimeras, commonly referred to as PROTACs, to effect removal of unwanted proteins by protein degradation (Scheepstra et al., Comp. Struct. Biotech. J. 2019, 17, 160-176).
Implementation Method 3
Ubiquitination of the protein is accomplished by an E3 ubiquitin ligase that binds to a protein and adds ubiquitin molecules to the protein, thus marking the protein for proteasome degradation.
Implementation Method 4
The ubiquitinated target protein is subsequently recognized by the proteasome, where it is degraded.
Data Source
AI summary
Provided herein are compounds of formula (I) and compositions thereof for modulating CAMKK2. In some embodiments, the compounds and compositions are provided for treatment of cancer and/or obesity.